{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:22:53Z","timestamp":1772173373237,"version":"3.50.1"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1012157","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000}}],"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019329","name":"Emerson Collective","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bisciotti Foundation Translational Fund"},{"name":"Maryland Innovation Initiative from TEDCO","award":["2019-MII-5200"],"award-info":[{"award-number":["2019-MII-5200"]}]},{"DOI":"10.13039\/100023581","name":"National Science Foundation Graduate Research Fellowship Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100023581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>The spread of cancer from organ to organ (metastasis) is responsible for the vast majority of cancer deaths; however, most current anti-cancer drugs are designed to arrest or reverse tumor growth without directly addressing disease spread. It was recently discovered that tumor cell-secreted interleukin-6 (IL-6) and interleukin-8 (IL-8) synergize to enhance cancer metastasis in a cell-density dependent manner, and blockade of the IL-6 and IL-8 receptors (IL-6R and IL-8R) with a novel bispecific antibody, BS1, significantly reduced metastatic burden in multiple preclinical mouse models of cancer. Bispecific antibodies (BsAbs), which combine two different antigen-binding sites into one molecule, are a promising modality for drug development due to their enhanced avidity and dual targeting effects. However, while BsAbs have tremendous therapeutic potential, elucidating the mechanisms underlying their binding and inhibition will be critical for maximizing the efficacy of new BsAb treatments. Here, we describe a quantitative, computational model of the BS1 BsAb, exhibiting how modeling multivalent binding provides key insights into antibody affinity and avidity effects and can guide therapeutic design. We present detailed simulations of the monovalent and bivalent binding interactions between different antibody constructs and the IL-6 and IL-8 receptors to establish how antibody properties and system conditions impact the formation of binary (antibody-receptor) and ternary (receptor-antibody-receptor) complexes. Model results demonstrate how the balance of these complex types drives receptor inhibition, providing important and generalizable predictions for effective therapeutic design.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1012157","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T14:24:32Z","timestamp":1717770272000},"page":"e1012157","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mechanistic computational modeling of monospecific and bispecific antibodies targeting interleukin-6\/8 receptors"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7552-9759","authenticated-orcid":true,"given":"Christina M. P.","family":"Ray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-2087","authenticated-orcid":true,"given":"Huilin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-3732","authenticated-orcid":true,"given":"Jamie B.","family":"Spangler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3481-7740","authenticated-orcid":true,"given":"Feilim","family":"Mac Gabhann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"issue":"16","key":"pcbi.1012157.ref001","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.ejca.2005.08.016","article-title":"The role of IL-6 and STAT3 in inflammation and cancer","volume":"41","author":"DR Hodge","year":"2005","journal-title":"Eur J Cancer"},{"issue":"9","key":"pcbi.1012157.ref002","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cncr.22999","article-title":"Interleukin-6 and its receptor in cancer","volume":"110","author":"DS Hong","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"pcbi.1012157.ref003","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-2143(96)90005-0","article-title":"In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors","volume":"128","author":"RC Hoch","year":"1996","journal-title":"J Lab Clin Med"},{"issue":"5","key":"pcbi.1012157.ref004","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.4049\/jimmunol.152.5.2467","article-title":"Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biologic effects","volume":"152","author":"F Petersen","year":"1994","journal-title":"J Immunol"},{"issue":"5","key":"pcbi.1012157.ref005","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.4049\/jimmunol.155.5.2587","article-title":"Regulation of the expression of IL-8 receptor A\/B by IL-8: possible functions of each receptor","volume":"155","author":"A Chuntharapai","year":"1995","journal-title":"J Immunol"},{"issue":"2","key":"pcbi.1012157.ref006","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10549-006-9328-3","article-title":"Significance of interleukin-6 (IL-6) in breast cancer (review).","volume":"102","author":"H Kn\u00fcpfer","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"pcbi.1012157.ref007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1158\/1541-7786.MCR-19-0595","article-title":"IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer","volume":"18","author":"JP Maynard","year":"2020","journal-title":"Mol Cancer Res"},{"issue":"9","key":"pcbi.1012157.ref008","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1002\/ijc.25562","article-title":"Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models","volume":"128","author":"Y Ning","year":"2011","journal-title":"Int J Cancer"},{"issue":"4","key":"pcbi.1012157.ref009","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1499-3872(14)60259-9","article-title":"Interleukin-6: a villain in the drama of pancreatic cancer development and progression","volume":"13","author":"R Holmer","year":"2014","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"9","key":"pcbi.1012157.ref010","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/ijc.22930","article-title":"Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells","volume":"121","author":"C Yao","year":"2007","journal-title":"Int J Cancer"},{"issue":"7","key":"pcbi.1012157.ref011","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ctrv.2012.04.007","article-title":"Interleukin-6 signaling pathway in targeted therapy for cancer","volume":"38","author":"Y Guo","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"15584","key":"pcbi.1012157.ref012","first-page":"1","article-title":"Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration","volume":"8","author":"H Jayatilaka","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"pcbi.1012157.ref013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3899\/jrheum.100717","article-title":"Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review","volume":"38","author":"JA Singh","year":"2011","journal-title":"J Rheumatol"},{"issue":"1","key":"pcbi.1012157.ref014","first-page":"1","article-title":"A window-of-opportunity trial of the CXCR1\/2 inhibitor reparixin in operable HER-2-negative breast cancer","volume":"22","author":"LJ Goldstein","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"66","key":"pcbi.1012157.ref015","doi-asserted-by":"crossref","first-page":"32556","DOI":"10.18632\/oncotarget.25863","article-title":"Tumor cell density regulates matrix metalloproteinases for enhanced migration","volume":"9","author":"H Jayatilaka","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"pcbi.1012157.ref016","doi-asserted-by":"crossref","first-page":"e1698","DOI":"10.1002\/wnan.1698","article-title":"Targeting cancer metastasis with antibody therapeutics","volume":"13","author":"H Yang","year":"2021","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"1","key":"pcbi.1012157.ref017","article-title":"Monoclonal antibodies in cancer therapy","volume":"12","author":"AM Scott","year":"2012","journal-title":"Cancer Immun"},{"key":"pcbi.1012157.ref018","first-page":"33","article-title":"Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy.","volume":"13","author":"E Cruz","year":"2019","journal-title":"Biologics: Targets & Therapy"},{"issue":"5","key":"pcbi.1012157.ref019","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tibtech.2004.03.006","article-title":"A revival of bispecific antibodies","volume":"22","author":"P Kufer","year":"2004","journal-title":"Trends Biotechnol"},{"key":"pcbi.1012157.ref020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.copbio.2019.01.017","article-title":"Emerging technologies in protein interface engineering for biomedical applications","volume":"60","author":"PJ Krohl","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"pcbi.1012157.ref021","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: design, therapy, perspectives.","volume":"12","author":"SE Sedykh","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"pcbi.1012157.ref022","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/19420862.2015.1022695","article-title":"Insights into the molecular basis of a bispecific antibody\u2019s target selectivity.","volume":"7","author":"Y Mazor","year":"2015","journal-title":"MAbs"},{"issue":"40098","key":"pcbi.1012157.ref023","first-page":"1","article-title":"Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence.","volume":"7","author":"Y Mazor","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"pcbi.1012157.ref024","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/19420862.2016.1141160","article-title":"The application of mathematical modelling to the design of bispecific monoclonal antibodies.","volume":"8","author":"Bergmann KR Steeg TJ van","year":"2016","journal-title":"MAbs"},{"issue":"13","key":"pcbi.1012157.ref025","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors","volume":"76","author":"SL Moores","year":"2016","journal-title":"Cancer Res"},{"key":"pcbi.1012157.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.","volume":"296","author":"J Neijssen","year":"2021","journal-title":"J Biol Chem"},{"issue":"8","key":"pcbi.1012157.ref027","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline.","volume":"18","author":"AF Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"pcbi.1012157.ref028","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1016\/j.ymthe.2022.07.008","article-title":"Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis","volume":"30","author":"H Yang","year":"2022","journal-title":"Mol Ther"},{"issue":"12","key":"pcbi.1012157.ref029","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.4049\/jimmunol.153.12.5682","article-title":"Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes","volume":"153","author":"A Chuntharapai","year":"1994","journal-title":"J Immunol"},{"key":"pcbi.1012157.ref030","volume-title":"Receptors: Models for Binding, Trafficking, and Signaling.","author":"DA Lauffenburger","year":"1996"},{"key":"pcbi.1012157.ref031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmolb.2020.615565","article-title":"Binding revisited\u2014avidity in cellular function and signaling.","volume":"7","author":"S Erlendsson","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"10","key":"pcbi.1012157.ref032","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design.","volume":"21","author":"SC Oostindie","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"41","key":"pcbi.1012157.ref033","doi-asserted-by":"crossref","first-page":"24689","DOI":"10.1074\/jbc.M115.651653","article-title":"Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor x c-MET Bispecific Antibody","volume":"290","author":"SW Jarantow","year":"2015","journal-title":"J Biol Chem"},{"issue":"S1","key":"pcbi.1012157.ref034","doi-asserted-by":"crossref","first-page":"S132","DOI":"10.1002\/jcph.1706","article-title":"Informing Development of Bispecific Antibodies Using Physiologically Based Pharmacokinetic-Pharmacodynamic Models: Current Capabilities and Future Opportunities.","volume":"60","author":"JP Gibbs","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"pcbi.1012157.ref035","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/cpt.1961","article-title":"Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology","volume":"108","author":"A Betts","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"pcbi.1012157.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2022.856961","article-title":"Physiological Considerations for Modeling in vivo Antibody-Target Interactions.","volume":"13","author":"T Dunlap","year":"2022","journal-title":"Front Pharmacol"},{"issue":"8","key":"pcbi.1012157.ref037","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1111\/bph.12106","article-title":"Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands","volume":"168","author":"G Vauquelin","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"1","key":"pcbi.1012157.ref038","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymeth.2013.07.017","article-title":"Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.","volume":"65","author":"BD Harms","year":"2014","journal-title":"Methods"},{"issue":"21","key":"pcbi.1012157.ref039","doi-asserted-by":"crossref","first-page":"11337","DOI":"10.1074\/jbc.M116.714287","article-title":"A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets","volume":"291","author":"JJ Rhoden","year":"2016","journal-title":"J Biol Chem"},{"issue":"5","key":"pcbi.1012157.ref040","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1080\/19420862.2016.1178437","article-title":"Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion","volume":"8","author":"BG Sengers","year":"2016","journal-title":"MAbs"},{"key":"pcbi.1012157.ref041","doi-asserted-by":"crossref","first-page":"108714","DOI":"10.1016\/j.mbs.2021.108714","article-title":"A general model of multivalent binding with ligands of heterotypic subunits and multiple surface receptors","volume":"342","author":"ZC Tan","year":"2021","journal-title":"Math Biosci"},{"issue":"9","key":"pcbi.1012157.ref042","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1080\/21645515.2017.1316909","article-title":"Tocilizumab (Actemra).","volume":"13","author":"M Sheppard","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"7","key":"pcbi.1012157.ref043","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"\u2018Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization.","volume":"9","author":"JBB Ridgway","year":"1996","journal-title":"Protein Eng Des Sel"},{"issue":"2","key":"pcbi.1012157.ref044","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jmb.2014.11.017","article-title":"An Improved Single-Chain Fab Platform for Efficient Display and Recombinant Expression","volume":"427","author":"JT Koerber","year":"2015","journal-title":"J Mol Biol"},{"key":"pcbi.1012157.ref045","article-title":"Characterization of the Integrin and Activation Steps Mediating Human Eosinophil and Neutrophil Adhesion to Chronically Inflamed Airway Endothelium","author":"CA McNulty","year":"1999","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"10","key":"pcbi.1012157.ref046","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1021\/bi00681a014","article-title":"Free energy and the kinetics of biochemical diagrams, including active transport","volume":"14","author":"TL Hill","year":"1975","journal-title":"Biochemistry"},{"issue":"6","key":"pcbi.1012157.ref047","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1529\/biophysj.103.038679","article-title":"How to Impose Microscopic Reversibility in Complex Reaction Mechanisms","volume":"86","author":"D Colquhoun","year":"2004","journal-title":"Biophys J"},{"issue":"1","key":"pcbi.1012157.ref048","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02918348","article-title":"Energy coupling and thermokinetic balancing in enzyme kinetics","volume":"12","author":"D Walz","year":"1988","journal-title":"Cell Biophys"},{"issue":"8","key":"pcbi.1012157.ref049","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/ed081p1206","article-title":"Principle of Detailed Balance in Kinetics","volume":"81","author":"RA Alberty","year":"2004","journal-title":"J Chem Educ"},{"issue":"15","key":"pcbi.1012157.ref050","first-page":"4157","article-title":"Effect of Bivalent Interaction upon Apparent Antibody Affinity: Experimental Confirmation of Theory Using Fluorescence Photobleaching and Implications for Antibody Binding Assays","volume":"52","author":"EN Kaufman","year":"1992","journal-title":"Cancer Res"},{"key":"pcbi.1012157.ref051","first-page":"67","volume-title":"In: Methods in Enzymology","author":"BD Harms","year":"2012"},{"key":"pcbi.1012157.ref052","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ab.2017.08.002","article-title":"Designing binding kinetic assay on the bio-layer interferometry (BLI) biosensor to characterize antibody-antigen interactions.","volume":"536","author":"V Kamat","year":"2017","journal-title":"Anal Biochem"},{"issue":"16","key":"pcbi.1012157.ref053","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1021\/ja311795d","article-title":"A Comprehensive Mathematical Model for Three-Body Binding Equilibria","volume":"135","author":"EF Douglass","year":"2013","journal-title":"J Am Chem Soc"},{"issue":"7","key":"pcbi.1012157.ref054","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/j.1460-2075.1996.tb00495.x","article-title":"Structure of a neutralizing antibody bound bivalently to human rhinovirus 2","volume":"15","author":"EA Hewat","year":"1996","journal-title":"EMBO J"},{"issue":"1","key":"pcbi.1012157.ref055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0006-3495(88)82929-1","article-title":"Size and structure of antigen-antibody complexes. Electron microscopy and light scattering studies","volume":"54","author":"R Murphy","year":"1988","journal-title":"Biophys J"},{"issue":"6","key":"pcbi.1012157.ref056","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1021\/bi00121a028","article-title":"Distances between the antigen-binding sites of three murine antibody subclasses measured using neutron and x-ray scattering","volume":"31","author":"TR Sosnick","year":"1992","journal-title":"Biochemistry"},{"issue":"1","key":"pcbi.1012157.ref057","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-2836(02)00244-9","article-title":"Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility","volume":"319","author":"EO Saphire","year":"2002","journal-title":"J Mol Biol"},{"issue":"2","key":"pcbi.1012157.ref058","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/19420862.2015.1007816","article-title":"Improving target cell specificity using a novel monovalent bispecific IgG design","volume":"7","author":"Y Mazor","year":"2015","journal-title":"MAbs"},{"issue":"2","key":"pcbi.1012157.ref059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.2","article-title":"A Mathematical Model for the Rational Design of Chimeric Ligands in Selective Drug Therapies.","volume":"2","author":"V Doldan-Martelli","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"pcbi.1012157.ref060","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1529\/biophysj.105.065300","article-title":"Effects of Receptor Clustering on Ligand Dissociation Kinetics: Theory and Simulations","volume":"89","author":"M Gopalakrishnan","year":"2005","journal-title":"Biophys J"},{"issue":"1","key":"pcbi.1012157.ref061","first-page":"1","article-title":"Impact of receptor clustering on ligand binding","volume":"5","author":"BR Care","year":"2011","journal-title":"BMC Syst Biol"},{"issue":"3","key":"pcbi.1012157.ref062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pcbi.1004752","article-title":"Simulation and Theory of Antibody Binding to Crowded Antigen-Covered Surfaces.","volume":"12","author":"C De Michele","year":"2016","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"pcbi.1012157.ref063","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4161\/cbt.11.4.14097","article-title":"Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile.","volume":"11","author":"G Garrido","year":"2011","journal-title":"Cancer Biology & Therapy"},{"issue":"24","key":"pcbi.1012157.ref064","first-page":"7008","article-title":"Influence of Affinity and Antigen Density on Antibody Localization in a Modifiable Tumor Targeting Model","volume":"60","author":"LS Zuckier","year":"2000","journal-title":"Cancer Res"},{"issue":"18","key":"pcbi.1012157.ref065","first-page":"4175","article-title":"Growth Inhibition of Human Lung Cancer Cell Lines by Interleukin 6 in Vitro: A Possible Role in Tumor Growth via an Autocrine Mechanism","volume":"53","author":"H Takizawa","year":"1993","journal-title":"Cancer Res"},{"issue":"5","key":"pcbi.1012157.ref066","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal Antibody Pharmacokinetics and Pharmacodynamics","volume":"84","author":"W Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"pcbi.1012157.ref067","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","article-title":"Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors","volume":"71","author":"SI Rudnick","year":"2011","journal-title":"Cancer Res"},{"issue":"3","key":"pcbi.1012157.ref068","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1124\/jpet.112.191999","article-title":"A Model-Based Approach to Predicting the Human Pharmacokinetics of a Monoclonal Antibody Exhibiting Target-Mediated Drug Disposition","volume":"341","author":"KT Luu","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"pcbi.1012157.ref069","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/psp4.12369","article-title":"Target-Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy.","volume":"8","author":"J Schropp","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"pcbi.1012157.ref070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10928-014-9401-1","article-title":"Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies","volume":"42","author":"VL Chudasama","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1012157","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T13:50:02Z","timestamp":1718891402000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1012157"}},"subtitle":[],"editor":[{"given":"Martin","family":"Meier-Schellersheim","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1012157","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.12.18.570445","asserted-by":"object"}]},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}